therapeutic_6

The last few decades have witnessed an acceleration in the discovery and development of therapeutic antibodies.

Respiratory syncytial virus (RSV) has recently gained much attention due to the approval of several drugs this year.On May 3, 2023, the U.S. Food and Drug Administration (FDA) authorized Arexvy, the first RSV vaccine for use in the United States.